Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR3 | P25089 | 7/20 | 0.34 |
| ▸ | FPR2 | P25090 | 7/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20807307 | 0.83 | FPR3 (0.38) | FPR3FPR2HSD11B1OPRK1 | |
| SCHEMBL20807218 | 0.83 | FPR3 (0.38) | FPR3FPR2HSD11B1OPRK1 | |
| SCHEMBL25519339 | 0.79 | HTT (0.36) | — | |
| SCHEMBL20807430 | 0.75 | FPR3 (0.36) | FPR3FPR2HSD11B1OPRK1 | |
| SCHEMBL28436207 | 0.75 | FPR3 (0.36) | FPR3FPR2HSD11B1OPRK1 | |
| SCHEMBL24829943 | 0.75 | FPR3 (0.36) | FPR3FPR2HSD11B1OPRK1 | |
| SCHEMBL20807391 | 0.75 | FPR3 (0.36) | FPR3FPR2HSD11B1OPRK1 | |
| SCHEMBL25520138 | 0.74 | HDAC3 (0.33) | FPR3FPR2OPRK1 | |
| SCHEMBL21122186 | 0.73 | FPR3 (0.36) | FPR3FPR2 | |
| SCHEMBL20789296 | 0.72 | GPR119 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-4108663-A1 | SUBSTITUTED ARYL COMPOUND | Simcere Pharmaceutical Co., Ltd. (CN) | 2022-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | RAD51, FANCI, BLM | FPR3 2323/4885FPR2 2183/4885HSD11B1 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.